

## CLAIMS

- Sub  
A6
- 1) A mammalian secreted group XII sPLA<sub>2</sub> containing a potential Ca<sup>2+</sup> binding segment GCGSP.
  - 2) The mammalian secreted group XII sPLA<sub>2</sub> according to Claim 1, comprising SEQ ID N°2.
  - 3) The mammalian secreted group XII sPLA<sub>2</sub> according to Claim 1, wherein said mammalian is a human.
  - 4) A nucleic acid molecule comprising an encoding nucleic sequence for a mammalian secreted group XII sPLA<sub>2</sub> or for a fragment of a mammalian secreted group XII sPLA<sub>2</sub> having SEQ ID N°2.
  - 5) The nucleic acid molecule according to Claim 4, comprising SEQ ID N°1.
  - 6) A polyclonal or monoclonal antibody directed against a secreted group XII sPLA<sub>2</sub> according to Claim 1, a derivative or a fragment of said antibody.
  - 7) A vector comprising at least one molecule of nucleic acid according to Claim 4, associated with adapted control sequences.

- 8) A cellular host transformed by one molecule of nucleic acid according to Claim 4.
- 9) A cellular host transformed by a vector according to Claim 7.
- 10) A nucleic and oligonucleotide probe prepared from one molecule of nucleic acid according to Claim 4.
- 11) A pharmaceutical composition comprising as an active agent at least one nucleic acid molecule according to Claim 4, or one protein according to Claim 1 or a derivative thereof.
- 12) A pharmaceutical composition according to Claim 11 which treats and/or prevents viral and bacterial infections.
- 13) A pharmaceutical composition according to Claim 11 which treats and/or prevents cancers.
- 14) A method for identifying a biologically active compound capable of inhibiting the catalytic activity of sPLA<sub>2</sub> according to Claim 1, wherein the compound is added to a cellular host according to Claim 8, and release of fatty acids and lysophospholipids is measured.